Cikova Andrea, Vavrincova-Yaghi Diana, Vavrinec Peter, Dobisova Anna, Gebhardtova Andrea, Flassikova Zora, Seelen Mark A, Henning Robert H, Yaghi Aktham
University Hospital Bratislava, Nemocnica Ruzinov, ICU, KAIM, Clinic of Anesthesiology and Intensive Care Medicine, Faculty of Medicine, Comenius University in Bratislava, Bratislava, Slovakia.
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University in Bratislava, Bratislava, Odbojarov 10, 832 32, Bratislava, Slovakia.
BMC Gastroenterol. 2017 Nov 28;17(1):131. doi: 10.1186/s12876-017-0695-5.
Post-transplant tuberculosis (PTTB) is a serious opportunistic infection in renal graft recipients with a 30-70 fold higher incidence compared to the general population. PTTB occurs most frequently within the first years after transplantation, manifesting as pulmonary or disseminated TB. Gastrointestinal TB (GITB) is a rare and potentially lethal manifestation of PTTB and may show delayed onset in renal transplant recipients due to the use of lower doses of immunosuppressants. Further, non-specificity of symptoms and the common occurrence of GI disorders in transplant recipients may delay diagnosis of GITB.
Here we report a rare survival case of isolated GITB in a renal transplant recipient, occurring seven years after transplantation. The patient's condition was complicated by severe sepsis with positive blood culture Staphylococcus haemolyticus, septic shock, multiple organ failure including acute respiratory distress syndrome (ARDS) and acute renal failure, requiring mechanical ventilation, vasopressor circulatory support and intermittent hemodialysis. Furthermore, nosocomial infections such as invasive aspergillosis and Pseudomonas aeruginosa occurred during hospitalization. Antituberculosis therapy (rifampicin, isoniazid, ethambutol and pyrazinamide) was initiated upon Mycobacterium confirmation. Moreover, treatment with voriconazole due to the Aspergillus flavus and meropenem due to the Pseudomonas aeruginosa was initiated, the former necessitating discontinuation of rifampicin. After 34 days, the patient was weaned from mechanical ventilation and was discharged to the pulmonary ward, followed by complete recovery.
This case offers a guideline for the clinical management towards survival of GITB in transplant patients, complicated by septic shock and multiple organ failure, including acute renal injury and ARDS.
移植后结核病(PTTB)是肾移植受者中一种严重的机会性感染,其发病率比普通人群高30至70倍。PTTB最常发生在移植后的头几年,表现为肺结核或播散性结核。胃肠道结核(GITB)是PTTB的一种罕见且可能致命的表现形式,由于使用较低剂量的免疫抑制剂,在肾移植受者中可能出现发病延迟。此外,症状的非特异性以及移植受者中胃肠道疾病的常见发生可能会延迟GITB的诊断。
在此,我们报告一例肾移植受者孤立性GITB的罕见存活病例,发生在移植后七年。患者病情因严重脓毒症合并血培养溶血葡萄球菌阳性、感染性休克、包括急性呼吸窘迫综合征(ARDS)和急性肾衰竭在内的多器官衰竭而复杂化,需要机械通气、血管活性药物循环支持和间歇性血液透析。此外,住院期间发生了医院感染,如侵袭性曲霉病和铜绿假单胞菌感染。确诊为结核分枝杆菌后开始抗结核治疗(利福平、异烟肼、乙胺丁醇和吡嗪酰胺)。此外,因黄曲霉感染开始使用伏立康唑治疗,因铜绿假单胞菌感染开始使用美罗培南治疗,前者需要停用利福平。34天后,患者脱机并转至肺病科病房,随后完全康复。
本病例为移植患者中合并感染性休克和多器官衰竭(包括急性肾损伤和ARDS)的GITB存活患者的临床管理提供了指导。